Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Veeva Systems Inc.    VEEV

VEEVA SYSTEMS INC.

(VEEV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Veeva : Medis Selects Veeva CRM to Deliver Personalized Experiences to Healthcare Professionals

share with twitter share with LinkedIn share with facebook
09/22/2020 | 05:01am EDT

Complete view of the customer enables field teams to drive relevant, timely, and compliant engagement across all channels

Veeva Systems (NYSE:VEEV) today announced that Medis has switched to multichannel Veeva CRM in 15 countries across Central and Eastern Europe to advance its commercial strategy and drive more efficient and effective interactions with healthcare professionals (HCPs).

“Veeva CRM gives our teams a flexible solution that adapts to the unique go to market strategies of every customer,” said Kristina Jerič, multichannel implementation lead at Medis. “Now, our field teams can get the customer insights they need to quickly drive targeted, relevant interactions with HCPs.”

Medis is a leading independent medical marketing company that specializes in the commercialization of innovative pharmaceutical products. The company needed a CRM solution to effectively execute their customers’ commercial and medical strategies with speed and compliance. With Veeva CRM, Medis can now efficiently deliver compliant, tailored experiences to HCPs across all channels, including face-to-face, email, and web.

“Veeva CRM offers Medis’ field teams advanced mobility, multichannel capabilities, and real-time insights to drive engagement with the right customer in the right channel at the right time,” said David Logue, senior vice president of commercial strategy at Veeva. “Medis’ field teams can now drive more efficient and effective HCP engagement while maintaining compliance.”

As part of multichannel Veeva CRM, Medis is implementing Veeva CRM, Veeva CLM, Veeva CRM Engage Meeting, and Veeva CRM Approved Email. Learn more about Veeva commercial solutions at Veeva Commercial & Medical Summit Online, Europe, November 17-18. The event is only open to life sciences industry professionals. Register for the virtual event at veeva.com/Summit.

Additional Information

For more on multichannel Veeva CRM, visit: veeva.com/eu/CRM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Medis

Medis is a medical marketing company focused on commercialization of innovative pharmaceutical products, with emphasis on specialty drugs, medical equipment and self-care brands. Medis aims at making the most advanced and effective medical treatments accessible to every patient in Central and Eastern Europe region, by leveraging its marketing know-how, scientific expertise and product knowledge. It is headquartered in the Ljubljana, Slovenia, founded in 1989, and employs more than 350. In 2019, the company achieved sales of €118 million. Learn more about Medis at www.medis.health/en/.

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about VEEVA SYSTEMS INC.
10/28VEEVA : Bavarian Nordic Adopting Veeva CRM and Veeva Vault PromoMats for Digital..
BU
10/28VEEVA : Bavarian Nordic Adopting Veeva CRM and Veeva Vault PromoMats for Digital..
BU
10/27VEEVA : Teams With Life Sciences to Offer Industrywide Source for Key Contacts, ..
BU
10/27VEEVA : Teams with Life Sciences to Offer Industrywide Source for Key Contacts, ..
BU
10/20VEEVA : Chief Medical Officers to Keynote at 2020 Veeva MedTech Summit Online
PU
10/20VEEVA : Chief Medical Officers from Boston Scientific, Illumina, Johnson & Johns..
BU
10/14VEEVA : Exact Sciences Selects Veeva Vault Clinical Suite to Help Accelerate Inn..
BU
10/14VEEVA : Exact Sciences Selects Veeva Vault Clinical Suite to Help Accelerate Inn..
BU
10/12VEEVA : Leading Companies Accelerating Clinical Trials with Veeva Vault CDMS
BU
10/12VEEVA : More Than 300 Companies Adopt Vault Quality Applications to Unify Global..
BU
More news
Financials (USD)
Sales 2021 1 420 M - -
Net income 2021 340 M - -
Net cash 2021 1 500 M - -
P/E ratio 2021 135x
Yield 2021 -
Capitalization 42 937 M 42 937 M -
EV / Sales 2021 29,2x
EV / Sales 2022 24,0x
Nbr of Employees 3 501
Free-Float 89,5%
Chart VEEVA SYSTEMS INC.
Duration : Period :
Veeva Systems Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VEEVA SYSTEMS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 301,14 $
Last Close Price 284,68 $
Spread / Highest target 17,7%
Spread / Average Target 5,78%
Spread / Lowest Target -21,0%
EPS Revisions
Managers
NameTitle
Peter P. Gassner Chief Executive Officer & Director
Tom Schwenger President & Chief Operating Officer
Gordon Ritter Chairman
Brent Bowman Chief Financial Officer
Catherine Allshouse Global Chief Information Officer & Head-Operations
Sector and Competitors
1st jan.Capitalization (M$)
VEEVA SYSTEMS INC.102.39%42 937
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED130.00%36 944
OMNICELL, INC.8.60%3 679
PRO MEDICUS LIMITED47.29%2 449
B-SOFT CO.,LTD.12.88%2 355
SECTRA AB (PUBL)36.57%2 325